30 March 2015

HBM



HBM BioCapital II LP, Jersey, managed by HBM Partners AG, Zug, one of the leading Swiss Private Equity investors and global leaders in healthcare-focused investments, has acquired a minority stake in APR Applied Pharma Research SA, Balerna. APR is a Swiss independent developer of science driven, patent protected healthcare products. The company identifies, develops and licenses value added products designed to address patient or consumer needs in selected therapeutical areas on a global basis.

Lucas Hänni (Counsel, Corporate/M&A) and Samuel Lieberherr (Associate, Corporate/M&A) of Walder Wyss have acted as legal advisor to HBM in the transaction.

News

News

30 March 2015

HBM

HBM BioCapital II LP, Jersey, managed by HBM Partners AG, Zug, one of the leading Swiss Private Equity investors and global leaders in healthcare-focused investments, has acquired a minority stake in APR Applied Pharma Research SA, Balerna. APR is a Swiss independent developer of science driven, patent protected healthcare products. The company identifies, develops and licenses value added products designed to address patient or consumer needs in selected therapeutical areas on a global basis.

Lucas Hänni (Counsel, Corporate/M&A) and Samuel Lieberherr (Associate, Corporate/M&A) of Walder Wyss have acted as legal advisor to HBM in the transaction.